Zejula 200 Pill - blue oval, 16mm
Generic Name: niraparib
Pill with imprint Zejula 200 is Blue, Oval and has been identified as Zejula 200 mg. It is supplied by GlaxoSmithKline.
Zejula is used in the treatment of Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer and belongs to the drug class PARP inhibitors. Zejula 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Zejula 200
Zejula
- Generic Name
- niraparib
- Imprint
- Zejula 200
- Strength
- 200 mg
- Color
- Blue
- Size
- 16.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- PARP inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- GlaxoSmithKline
- National Drug Code (NDC)
- 00173-0912
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Doxil
Doxil is used for kaposi's sarcoma, multiple myeloma, ovarian cancer
More about Zejula (niraparib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (58)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.